

## Continuing statin after adverse Rx tied to lower cardiac risk

July 25 2017



(HealthDay)—For patients with an adverse reaction to a statin, continued



statin prescriptions are associated with lower incidence of cardiovascular events and death, according to a study published online July 25 in the *Annals of Internal Medicine*.

Huabing Zhang, M.D., from the Peking Union Medical College Hospital in Beijing, and colleagues conducted a <u>retrospective cohort study</u> to examine the correlation between continuation of <u>statin therapy</u> after an adverse reaction and clinical outcomes. Participants had a presumed adverse reaction to a statin between 2000 and 2011.

The researchers found that 81 percent of the <u>adverse reactions</u> to statins were identified from electronic provider notes. Overall, 70.7 percent of the 28,266 study patients continued receiving statin prescriptions after the adverse reaction. The cumulative incidence of the composite primary outcome (time to a cardiovascular event [myocardial infarction or stroke] or death) was 12.2 and 13.9 percent for patients with continued statin prescriptions versus those without (difference, 1.7 percent; 95 percent confidence interval, 0.8 to 2.7 percent; P

"Continued statin prescriptions after an adverse reaction were associated with a lower incidence of death and <u>cardiovascular events</u>," the authors write.

Two authors disclosed financial ties to the pharmaceutical industry.

More information: Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Copyright © 2017 HealthDay. All rights reserved.

Citation: Continuing statin after adverse Rx tied to lower cardiac risk (2017, July 25) retrieved



20 April 2024 from <a href="https://medicalxpress.com/news/2017-07-statin-adverse-rx-tied-cardiac.html">https://medicalxpress.com/news/2017-07-statin-adverse-rx-tied-cardiac.html</a>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.